With 4.17 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.35 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $74.525 whereas the lowest price it dropped to was $71.86. The 52-week range on DXCM shows that it touched its highest point at $142.00 and its lowest point at $62.34 during that stretch. It currently has a 1-year price target of $96.18. Beta for the stock currently stands at 1.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DXCM was up-trending over the past week, with a rise of 5.71%, but this was up by 8.09% over a month. Three-month performance surged to 0.23% while six-month performance fell -44.08%. The stock lost -26.25% in the past year, while it has lost -41.55% so far this year. A look at the trailing 12-month EPS for DXCM yields 1.67 with Next year EPS estimates of 2.03. For the next quarter, that number is 0.52. This implies an EPS growth rate of 12.02% for this year and 19.17% for next year.
Float and Shares Shorts:
At present, 385.40 million DXCM shares are outstanding with a float of 385.37 million shares on hand for trading. On 2024-10-31, short shares totaled 9.36 million, which was 240.0 higher than short shares on 1727654400. In addition to Mr. Kevin Ronald Sayer as the firm’s Executive Chairman, CEO & President, Mr. Jacob Steven Leach serves as its Executive VP & COO.
Institutional Ownership:
Through their ownership of 0.98483 of DXCM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, DXCM reported revenue of $994200000.0 and operating income of $152000000.0. The EBITDA in the recently reported quarter was $237400000.0 and diluted EPS was $0.34.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DXCM since 12 analysts follow the stock currently. There are 10 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DXCM analysts setting a high price target of 120.0 and a low target of 75.0, the average target price over the next 12 months is 95.305. Based on these targets, DXCM could surge 65.45% to reach the target high and rise by 3.41% to reach the target low. Reaching the average price target will result in a growth of 31.4% from current levels.
Analysts have provided yearly estimates in a range of $1.73261 being high and $1.64299 being low. For DXCM, this leads to a yearly average estimate of $1.70274. The surprise factor in the prior quarter was $0.39. Based on analyst estimates, the high estimate for the next quarter is $0.45 and the low estimate is $0.33. The average estimate for the next quarter is thus $0.4.
